TQB3702
/ Sino Biopharm
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
March 05, 2025
Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)
(clinicaltrials.gov)
- P2 | N=120 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
New P2 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
November 20, 2024
TQB3702-II-02: A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
(clinicaltrials.gov)
- P2 | N=80 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
August 22, 2024
A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
(clinicaltrials.gov)
- P2 | N=80 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
New P2 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
August 12, 2024
TQB3702-I-02: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetic of TQB3702 Tablets in Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
June 07, 2024
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetic of TQB3702 Tablets in Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=40 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
New P1 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
January 18, 2024
A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy
(clinicaltrials.gov)
- P1 | N=208 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
New P1 trial • Hematological Disorders • Hematological Malignancies • Oncology
November 09, 2022
Tolerability and Pharmacokinetics Study of TQB3702 Tablets in Hematologic Tumor Subjects
(clinicaltrials.gov)
- P1 | N=137 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
New P1 trial • Hematological Disorders • Hematological Malignancies • Oncology
1 to 7
Of
7
Go to page
1